Donate Register

NP001

NP001 may lower the levels of activated cytotoxic macrophages in people with ALS reducing inflammation and further injury to the motor nerves.

Status
Type:	Small Molecule
Status:	Phase II
Sponsor:	Neuraltus Pharmaceuticals

TDI Says:

A Phase II clinical trial failed to meet statistical significance, but a post hoc analysis suggested evidence of subgroup response. We are hopeful that the next trial will be designed and powered in a way to facilitate an accurate understanding of this compound vs. placebo. We urge caution in the reliance on historical controls and post hoc analysis alone to support advancement of any drug through the clinical trial process.

Our Work on NP001

There is no internal work posted

Other Published Results

There are no published results available

ALS Today Magazine Articles

Symphony in M

Methodist Neurological Institute’s Stanley Appel MD talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them looking forward.

Like a good neighbor, microglia are there?

In Brief: Microglia can be irritating to people with ALS. But according to a new study, these immune protectors may actually hold the key to keeping the disease in check.

NP001, a quiet riot for ALS?

CPMC's Forbes Norris ALS Clinic Director neurologist Bob Miller MD talks NP001 and its potential for people with ALS going forward.

ALS/MND 2012: Trials & Tribulations

Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.

Forum Discussion

Forum posts do not necessarily reflect TDI opinion.

DISCUSSION TITLE	POSTS	LAST ACTIVE
On the subject of NP001, a macrophage activation regulator for ALS	139	11/16/2011
Neuraltus	2454	11/15/2012

Visit the forums >

Comment on this Topic

(All comments are moderated before they appear here.)

Immunomodulation

Find this useful?
Help us fund more science:

Donate